- This event has passed.
International Dermatology Speaker Tour
28 August @ 6:30 pm - 9:00 pm
Lilly invites you to join international expert Dr Laura Savage and local expert A/Prof Peter Foley for an interactive discussion on:
- EULAR guidelines on progression from PsO to PsA
- The role of dermatologists in the early diagnosis of PsA
- Whether biologics can delay the progression from PsO to PsA
- Biologic choice in joints and challenging body areas like nails and scalp
|Melbourne (dinner meeting)||Zagame's House, 66 Lygon Street Carlton 3053|
|Adelaide (live stream)||Chianti, 160 Hutt St Adelaide SA 5000|
|Brisbane (live stream)||Darling & Co, 157 Given Terrace Paddington QLD 4064|
|6:30pm||Arrival and registration|
|7:15pm||Presentation and discussion with Dr Savage and A/Prof Foley|
Dr Laura Savage
MBChB, BSc(Hons), MRCP (UK), MRCP (Dermatology), PhD
Dr Laura Savage is a Consultant Medical Dermatologist (Leeds Teaching Hospitals NHS Trust) and Honorary Senior Lecturer (Faculty of Medicine and Health, University of Leeds). She co-leads the complex psoriatic disease, atopic dermatitis and tertiary hidradenitis suppurativa services and has extensive experience in utilising targeted immunomodulatory therapies across a number of IMIDs.
Dr Savage’s research interests cross the boundaries of both dermatology and rheumatology and relate primarily to the development of strategies to detect and manage early psoriatic arthritis in patients with psoriasis.
Aside from her role as an elected board member for the Group for Research in Psoriasis and Psoriatic Arthritis (GRAPPA), Dr Savage is an elected committee member of the British Society of Medical Dermatology, an invited author/member of the EULAR Task Force on Points to Consider for the definition of clinical and imaging features suspicious for progression to psoriatic arthritis, and part of the taskforce currently updating the EULAR recommendations for management of psoriatic arthritis with pharmacological therapies. She actively participates in clinical education on a national and international level for GRAPPA, the BSMD and the pharmaceutical industry.